Prognostic value of growth differentiation factor-15 in Chinese patients with heart failure: A prospective observational study

Wang, Hua; Chen, Qingyong; Li, Yingying; Jing, Xianchao; Yang, Jiefu

doi:10.5603/cj.a2017.0068

Cited by 9 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In chronic HFrEF, GDF‐15 served as a significant predictor for all‐cause mortality (Table ) even after multivariable adjustment for demographic factors and established biomarkers as hs‐TnT and Nt‐proBNP . GDF‐15 was shown to independently predict death or first HF rehospitalization in both HF subtypes even after adjusting for important clinical predictors including hs‐TnT and Nt‐proBNP .…”

Section: Next‐generation Biomarkers Under Researchmentioning

confidence: 98%

Biomarkers for heart failure: small molecules with high clinical relevance

2018

View full text Add to dashboard Cite

Heart failure (HF) is a rising epidemic due to the ageing population and progress in all areas of medicine. Thus, research efforts are made to ensure a timely diagnosis, to improve prognosis and treatment of the disease and to facilitate risk prediction at the population level. Because of their noninvasive determination with mostly high sensitivity and accuracy, circulating blood biomarkers are becoming increasingly important for daily clinical practice. Natriuretic peptides, especially B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (Nt-proBNP) and midregional pro-atrial natriuretic peptide (MR-proANP) and cardiac troponins are established blood biomarkers in HF diagnosis and prognosis of HF-related outcomes. Inflammatory molecules as C-reactive protein (CRP) may have added value in anti-inflammatory therapy guidance. Next-generation biomarkers including soluble source of tumorigenicity 2 (sST2), growth differentiation factor-15 (GDF-15), galectin-3 (Gal-3) and diverse microribonucleic acids (miRNAs) may have additional benefit in assessment of cardiac remodeling or differentiation of HF subtypes. Multimarker approaches containing different combinations of established and novel biomarkers might improve HF risk prediction at the population level once they are used on top of clinical variables.

show abstract

Section: Next‐generation Biomarkers Under Researchmentioning

confidence: 98%

Biomarkers for heart failure: small molecules with high clinical relevance

2018

View full text Add to dashboard Cite

show abstract

“…Currently, cardiac ultrasound (CUS) [5,15,16] and CMRI [5,17] are the major tools for the evaluation of ventricular remodeling and myocardial fibrosis at the international level. Above that, some biological indicators can also reflect the progress of fibrosis, such as ST2 and galectin-3 [5,[18][19][20]. In this trial, patients who have AMI and who receive PCI within 10 days will be the subjects, and the evaluation methods will include CUS; the T1 mapping sequence, cine sequence, and late gadolinium enhancement (LGE) sequence of CMRI; and measurements of biological indicators that reflect the progress of fibrosis.…”

Section: Discussionmentioning

confidence: 99%

Tongmai Yangxin intervening in myocardial remodeling after PCI for coronary heart disease: study protocol for a double-blind, randomized controlled trial

Wang

et al. 2020

Trials

View full text Add to dashboard Cite

Background: Coronary heart disease (CHD) has become a common cardiovascular disease that seriously threatens the health of people. As reperfusion in the early phase and drug therapy, especially percutaneous coronary intervention (PCI), have become widely used in the clinic, the mortality of acute myocardial infarction in the short term has been reduced significantly. In addition, in 40%-56% of patients who experience myocardial infarction, cardiac dysfunction occurs and about 25%-33% develop heart failure. Methods: This study was designed as a multicenter, double-blind, randomized, placebo-controlled, parallelgroup, superiority trial. Participants were randomly assigned in a 1:1 ratio through a centrally controlled, computer-generated, simple randomization schedule. The primary outcome was left ventricular end-diastolic volume index = left ventricular end-diastolic volume/body surface area. The combined secondary outcomes include traditional Chinese medicine syndrome score, echocardiogram results, 6-minute walk test results, Seattle Angina Questionnaire score, cardiac magnetic resonance imaging results, biological indicators, dynamic electrocardiogram results, and experiment event rate. Assessments will be performed at baseline and at 4, 8, and 12 weeks after randomization. Discussion: This trial will demonstrate that the addition of a Tongmai Yangxin pill (TMYX) to conventional treatment will intervene in the development of cardiac remodeling and cardiac dysfunction.

show abstract

“…Clinical studies also observed a higher circulating concentration of GDF-15 in patients with CHF compared with healthy individuals (9)(10)(11). Moreover, certain studies in patients with CHF revealed that GDF-15 level was positively correlated and the disease severity, indicating that GDF-15 might act as a novel prognostic biomarker of CHF in risk stratification and prediction of adverse outcomes (12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

A Meta-Analysis of Growth Differentiation Factor-15 and Prognosis in Chronic Heart Failure

Luo

Duan

Song

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: Previous studies had reported increased circulating concentrations of growth differentiation factor-15 (GDF-15) in chronic heart failure (CHF), suggesting the potential prognostic significance of GDF-15 in this setting. To verify the relationship between the circulating GDF-15 levels and prognosis of CHF patients, we conducted an updated evidence-based meta-analysis.Methods: A comprehensive literature retrieval of PubMed, EMBASE, and Cochrane library was performed to collect the qualified studies that analyzed the prognostic value of GDF-15 in CHF from the inception of these online databases to September 25, 2021. The hazard ratio (HR) calculated for logGDF-15 of all-cause death and the related 95% confidence interval (CI) in multivariate analysis were used to measure the effect size. Additionally, subgroup analyses stratified by characteristics of the study participants were conducted for incremental evidence of GDF-15 in CHF with different clinical status.Results: A total of ten eligible studies involving 6,244 CHF patients were finally taken into the quantitative analysis. Results in the random-effects model indicated that there was an increased risk of 6% in all-cause mortality with a per 1LnU increase in baseline GDF-15 concentration (HR: 1.06, 95% CI: 1.03–1.10, P < 0.001). In stratified analyses, the association of GDF-15 with risk of all-cause mortality was found among chronic ischemic HF patients (HR:1.75, 95%CI: 1.24–2.48, P = 0.002), while the association was not found among chronic nonischemic HF patients (HR:1.01, 95%CI: 1.00–1.02, P = 0.219).Conclusion: The elevated GDF-15 is associated with an increased risk of all-cause mortality in CHF, especially, among CHF patients with ischemic etiology. The circulating GDF-15 might be a prognostic indicator in CHF patients.Registration Number:https://www.crd.york.ac.uk/PROSPERO; CRD42020210796.

show abstract

Prognostic value of growth differentiation factor-15 in Chinese patients with heart failure: A prospective observational study

Abstract: Plasma GDF-15 is an independent predictor of all-cause mortality in Chinese patients with HF. It may potentially be used to stratify and prognosticate HF patients.

Cited by 9 publications

References 27 publications

Biomarkers for heart failure: small molecules with high clinical relevance

Biomarkers for heart failure: small molecules with high clinical relevance

Tongmai Yangxin intervening in myocardial remodeling after PCI for coronary heart disease: study protocol for a double-blind, randomized controlled trial

A Meta-Analysis of Growth Differentiation Factor-15 and Prognosis in Chronic Heart Failure

Contact Info

Product

Resources

About